Skip to main content

Advertisement

SpringerLink
Log in

The impact of chemotherapy on cognitive outcomes in adults with primary brain tumors

  • Effects of Standard of Art Treatment
  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Abstract

There is growing recognition that chemotherapy may have short and long term impact on cognitive function of cancer patients. However, the impact of chemotherapy on the cognition of adult patients with primary brain tumor has not been extensively studied. This article will review the evidence for both positive and negative impact of chemotherapy on cognitive function of adult brain tumor patients as well as potential confounding factors.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Janelsins MC, Kohli S, Mohile SG et al (2011) An update on cancer- and chemotherapy-related cognitive dysfunction: current status. Semin Oncol 38:431–438

    Article  PubMed  Google Scholar 

  2. Wefel JS, Vardy J, Ahles T, Schagen SB (2011) International cognition and cancer task force recommendations to harmonise studies of cognitive function in patients with cancer. Lancet Oncol 12:703–708

    Google Scholar 

  3. Raffa RB, Tallarida RJ (2010) Effects on the visual system might contribute to some of the cognitive deficits of cancer chemotherapy-induced ‘chemo-fog’. J Clin Pharm Ther 35:249–255

    Article  PubMed  CAS  Google Scholar 

  4. Dietrich J, Han R, Yang Y et al (2006) CNS progenitor cells and oligodendrocytes are targets of chemotherapeutic agents in vitro and vivo. J Biol 5:1–23

    Article  Google Scholar 

  5. Dietrich J, Monje M, Wefel J et al (2008) Clinical patterns and biological correlates of cognitive dysfunction associated with cancer therapy. Oncologist 13:1285–1295

    Article  PubMed  Google Scholar 

  6. Saykin AJ, Ahles TA, McDonald BC (2003) Mechanisms of chemotherapy-induced cognitive disorders: neuropsychological, pathophysiological, and neuroimaging perspectives. Semin Clin Neuropsychiatry 8:201–216

    Article  PubMed  Google Scholar 

  7. Petzold A, Mondria T, Kuhle J et al (2010) Evidence for acute neurotoxicity after chemotherapy. Ann Neurol 68:806–815

    Article  PubMed  Google Scholar 

  8. Lucas MR (2010) The impact of chemo brain on the patient with a high-grade glioma. Adv Exp Med Biol 678:21–25

    Article  PubMed  Google Scholar 

  9. Kaleita TA, Wellisch DK, Cloughesy TF et al (2004) Prediction of neurocognitive outcome in adult brain tumor patients. J Neurooncol 67:245–253

    Article  PubMed  Google Scholar 

  10. Correa DD (2010) Neurocognitive function in brain tumors. Curr Neurol Neurosci Rep 10:232–239

    Article  PubMed  Google Scholar 

  11. Fietta P, Fietta P, Delsante G (2009) Central nervous system effects of natural and synthetic glucocorticoids. Psychiatry Clin Neurosci 63(5):613–622

    Article  PubMed  CAS  Google Scholar 

  12. Baile WF (1996) Neuropsychiatric disorders in cancer patients. Curr Opin Oncol 8(3):182–187

    Article  PubMed  CAS  Google Scholar 

  13. Béhin A, Delattre JY (2004) Complications of radiation therapy on the brain and spinal cord. Semin Neurol 24(4):405–417

    Article  PubMed  Google Scholar 

  14. Correa DD, Maron L, Harder H et al (2007) Cognitive functions in primary central nervous system lymphoma: literature review and assessment guidelines. Ann Oncol 18:1145–1151

    Article  PubMed  CAS  Google Scholar 

  15. Sandor V, Stark-Vancs V, Pearson D et al (1998) Phase II trial of chemotherapy alone for primary CNS and intraocular lymphoma. J Clin Oncol 16:3000–3006

    PubMed  CAS  Google Scholar 

  16. Correa DD, Anderson ND, Glass A et al (2003) Cognitive functions in primary central nervous system lymphoma patients treated with chemotherapy and stem cell transplantation: preliminary findings. Clin Adv Hematol Oncol 1:490

    PubMed  Google Scholar 

  17. Fliessbach K, Urbach H, Helmstaedter C et al (2003) Cognitive performance and magnetic resonance imaging findings after high-dose systemic and intraventricular chemotherapy for primary central nervous system lymphoma. Arch Neurol 60:563–568

    Article  PubMed  Google Scholar 

  18. Fliessbach K, Helmstaedter C, Urbach H et al (2005) Neuropsychological outcome after chemotherapy for primary CNS lymphoma: a prospective study. Neurology 64:1184–1188

    Article  PubMed  CAS  Google Scholar 

  19. Pels H, Schmidt-Wolf IGH, Glasmacher A et al (2003) Primary central nervous system lymphoma: results of a pilot study and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy. J Clin Oncol 21:4489–4495

    Article  PubMed  CAS  Google Scholar 

  20. Schlegel U, Pels H, Glasmacher A et al (2001) Combined systemic and intraventricular chemotherapy in primary CNS lymphoma: a pilot study. J Neurol Neurosurg Psychiatr 71:118–122

    Article  PubMed  CAS  Google Scholar 

  21. Herrlinger U, Kuker W, Uhl M et al (2005) NOA-03 trial of high-dose methotrexate in primary central nervous system lymphoma: final report. Ann Neurol 57:843–847

    Article  PubMed  CAS  Google Scholar 

  22. McAllister LD, Doolittle ND, Guastadisegni PE et al (2000) Cognitive outcomes and long-term follow-up results after enhanced chemotherapy delivery for primary central nervous system lymphoma. Neurosurgery 46:51–60

    Article  PubMed  CAS  Google Scholar 

  23. Correa DD, DeAngelis LM, Shi W et al (2004) Cognitive functions in survivors of primary central nervous system lymphoma. Neurology 62:548–555

    Article  PubMed  CAS  Google Scholar 

  24. Wick W, Hartmann C, Engel C et al (2009) NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J Clin Oncol 27:5874–5880

    Article  PubMed  CAS  Google Scholar 

  25. Lassman AB, Iwamoto FM, Cloughesy TF et al (2011) International retrospective study of over 1000 adults with anaplastic oligodendroglial tumors. Neuro Oncol 13:649–659

    Article  PubMed  Google Scholar 

  26. Abrey LE, Childs BH, Paleologos N et al (2006) High-dose chemotherapy with stem cell rescue as initial therapy for anaplastic oligodendroglioma: long-term follow-up. Neuro Oncol 8:183–188

    Article  PubMed  CAS  Google Scholar 

  27. A phase III intergroup study of radiotherapy versus temozolomide alone versus radiotherapy with concomitant and adjuvant temozolomide for patients with 1p/19q codeleted anaplastic glioma. ClinicalTrials.gov identifier: NCT00887146

  28. Soffietti R, Baumert BG, Bello L (2010) European federation of neurological societies. Guidelines on management of low-grade gliomas: report of an EFNS-EANO task force. Eur J Neurol 17(9):1124–1133

    Article  PubMed  CAS  Google Scholar 

  29. Mason WP, Krol GS, DeAngelis LM (1996) Low-grade oligodendroglioma responds to chemotherapy. Neurology 46(1):203–207

    Article  PubMed  CAS  Google Scholar 

  30. Brada M, Viviers L, Abson C et al (2003) Phase II study of primary temozolomide chemotherapy in patients with WHO grade II gliomas. Ann Oncol 14(12):1715–1721

    Article  PubMed  CAS  Google Scholar 

  31. Kesari S, Schiff D, Drappatz J et al (2009) Phase II study of protracted daily temozolomide for low-grade gliomas in adults. Clin Cancer Res 15(1):330–337

    Article  PubMed  CAS  Google Scholar 

  32. Correa DD, Shi W, Thaler HT et al (2008) Longitudinal cognitive follow-up in low grade gliomas. J Neurooncol 86(3):321–327

    Article  PubMed  Google Scholar 

  33. van den Bent MJ, Wefel JS, Schiff D et al (2011) Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas. Lancet Oncol 12(6):583–593

    Article  PubMed  Google Scholar 

  34. A phase III randomized study of radiotherapy versus temozolomide in patients with low-grade gliomas. ClinicalTrials.gov identifier: NCT00182819

  35. A phase III study of radiation therapy with or without temozolomide for symptomatic or progressive low-grade gliomas. ClinicalTrials.gov identifier: NCT00978458

  36. van den Bent MJ, Carpentier AF, Brandes AA et al (2006) Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. J Clin Oncol 24:2715–2722

    Article  PubMed  Google Scholar 

  37. Cairncross G, Berkey B, Shaw E et al (2006) Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: intergroup radiation therapy oncology group trial 9402. J Clin Oncol 24:2707–2714

    Article  PubMed  CAS  Google Scholar 

  38. Wang M, Cairncross G, Shaw E et al (2010) Cognition and quality of life after chemotherapy plus radiotherapy (RT) vs. RT for pure and mixed anaplastic oligodendrogliomas: radiation therapy oncology group trial 9402. Int J Radiat Oncol Biol Phys 77:662–669

    Article  PubMed  Google Scholar 

  39. Taphoorn MJ, van den Bent MJ, Mauer ME et al (2007) Health-related quality of life in patients treated for anaplastic oligodendroglioma with adjuvant chemotherapy: results of a European Organisation for research and treatment of cancer randomized clinical trial. J Clin Oncol 25:5723–5730

    Article  PubMed  Google Scholar 

  40. Steinbach JP, Blaicher HP, Herrlinger U et al (2006) Surviving glioblastoma for more than 5 years: the patient’s perspective. Neurology 66:239–242

    Article  PubMed  CAS  Google Scholar 

  41. Hottinger AF, Yoon H, DeAngelis LM, Abrey LE (2009) Neurological outcome of long-term glioblastoma survivors. J Neurooncol 95:301–305

    Article  PubMed  Google Scholar 

  42. Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996

    Article  PubMed  CAS  Google Scholar 

  43. Stupp R, Hegi ME, Mason WP et al (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10:459–466

    Article  PubMed  CAS  Google Scholar 

  44. Hilverda K, Bosma I, Heimans JJ et al (2010) Cognitive functioning in glioblastoma patients during radiotherapy and temozolomide treatment: initial findings. J Neurooncol 97:89–94

    Article  PubMed  CAS  Google Scholar 

  45. Scott JG, Suh JH, Elson P et al (2011) Aggressive treatment is appropriate for glioblastoma multiforme patients 70 years old or older: a retrospective review of 206 cases. Neuro Oncol 13:428–436

    Article  PubMed  Google Scholar 

  46. Brandes AA, Franceschi E, Tosoni A et al (2009) Temozolomide concomitant and adjuvant to radiotherapy in elderly patients with glioblastoma: correlation with MGMT promoter methylation status. Cancer 115:3512–3518

    Article  PubMed  CAS  Google Scholar 

  47. Minniti G, De Sanctis V, Muni R et al (2008) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma in elderly patients. J Neurooncol 88:97–103

    Article  PubMed  CAS  Google Scholar 

  48. Sijben AE, McIntyre JB, Roldán GB et al (2008) Toxicity from chemoradiotherapy in older patients with glioblastoma multiforme. J Neurooncol 89:97–103

    Article  PubMed  Google Scholar 

  49. A randomized phase III study of temozolomide and short-course radiation versus short-course radiation alone in the treatment of newly diagnosed glioblastoma multiforme in elderly patients. Clinicaltrials.gov identifier: NCT00482677

  50. Gállego Pérez-Larraya J, Ducray F, Chinot O et al (2011) Temozolomide in elderly patients with newly diagnosed glioblastoma and poor performance status: an ANOCEF phase II trial. J Clin Oncol 29(22):3050–3055

    Article  PubMed  Google Scholar 

  51. Wefel JS, Cloughesy T, Zazzali JL et al (2011) Neurocognitive function in patients with recurrent glioblastoma treated with bevacizumab. Neuro Oncol 13:660–668

    Article  PubMed  CAS  Google Scholar 

Download references

Conflict of interest statement

The author declares that she has no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Neurology, University Hospital Zurich, Frauenklinikstrasse 26, 8091, Zurich, Switzerland

    Lauren E. Abrey

Authors
  1. Lauren E. Abrey
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lauren E. Abrey.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Abrey, L.E. The impact of chemotherapy on cognitive outcomes in adults with primary brain tumors. J Neurooncol 108, 285–290 (2012). https://doi.org/10.1007/s11060-012-0807-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11060-012-0807-6

Keywords

Search

Navigation